9-ING-41 in Patients with Advanced Cancers
[vc_row][vc_column][vc_column_text css=""] Background: A protein called GSK-3β plays a role in cancer by helping cancer cells grow, survive, and resist treatment. High levels of this protein have been found in many different cancers. 9-ING-41 is a new type of drug that blocks GSK-3β. Earlier lab studies have found...
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory Renal medullary carcinoma
[vc_row][vc_column][vc_column_text css=""] Background: Some aggressive cancers have missing genes in their tumors, specifically SMARCB1 or SMARCA4. These types of tumors are often harder to treat and may not respond well to standard therapies. This study is testing two immunotherapy drugs: Tiragolumab blocks a protein called TIGIT, which activates the...
Stereotactic Radiation Therapy (SABR) With or Without Immunotherapy for Patients With Unresectable or Metastatic Kidney Cancer (SAMURAI)
[vc_row][vc_column][vc_column_text css=""] Background: Stereotactic body radiation therapy (SABR) is a type of radiation therapy that uses special equipment to deliver radiation to tumors with high precision. This method may kill tumor cells with few radiation doses over a shorter period, causing less damage to normal tissue. Immunotherapy, such...
A Study of MK-4700 Alone or With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
[vc_row][vc_column][vc_column_text css=""] Background: MK-4700 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works...
A Study of BMS-986488 as Monotherapy and Combination Therapy in Patients with Advanced Malignant Tumors
[vc_row][vc_column][vc_column_text css=""] Background: BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body's immune system to recognize and attack cancer cells. Since this...
A Study of BMS-986340 Alone or in Combination with Nivolumab for Patients with Advanced Kidney Cancer
Background: Nivolumab (Opdivo®) is a Health Canada-approved immunotherapy for the treatment of kidney cancer and works by targeting a molecule called PD-1. Blocking the PD-1 molecule helps prime the body’s immune defences to more effectively target and destroy cancer cells; these therapies are often called immune...
A Study of GSK4381562 Alone or in Combination with Dostarlimab or GSK4428859A for Patients with Advanced Kidney Cancer
Background: GSK4381562, Dostarlimab, and GSK4428859A belong to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Dostarlimab targets the immune checkpoint molecule PD-1. This is similar to Nivolumab...
A Study of MDNA11 Alone or in Combination with Pembrolizumab in Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. MDNA11 is an experimental cancer therapy that...
A Study of KFA115 Alone or in Combination with Tislelizumab in Patients with Advanced Kidney Cancer
Background: Tislelizumab belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Tislelizumab targets the immune checkpoint molecule PD-1. This is similar to Nivolumab (Opdivo®), which is...
A Study of 23ME-00610 in Patients with Advanced Kidney Cancer
Background: 23ME-00610 belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Some notable approved immune checkpoint inhibitors for kidney cancer include Nivolumab (Opdivo®), Ipilimumab (Yervoy®),...
A Study of Different Immune and Targeted Therapies for 2nd Line (or higher) Treatment of Kidney Cancer (Substudy 03B)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate and strengthen the body’s immune response against cancer cells. Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor...
A Study of Combination Durvalamab + Savolitinib versus Sunitinib or Durvalamab Alone in Patients with Papillary Kidney Cancer
Background: Durvalamab (Imfinzi®) is a Health Canada approved immunotherapy that is currently used in the treatment of lung cancer, but is similar to another drug called Atezolizumab (Tecentriq®) which is already approved for the treatment of Kidney Cancer in Canada. These drugs work by targeting a...
A Study of Combination Chemotherapy in Patients with Wilms Tumours
Background: Wilms tumour is a rare type of kidney cancer that primarily affects children. For most patients, the first line of treatment is surgery to remove the affected kidney (nephrectomy). This may be accompanied by either radiation treatment, chemotherapy, or both, depending on the size and...
A Study of OC-001 Alone or in Combination with a PD-L1 Inhibitor in Patients With Advanced Solid Tumours
Background: OC-001 is an experimental immunotherapy drug that works by targeting a molecule called TNF. This type of treatment works by preventing inflammation in the body and enhancing the anti-cancer effect of certain other treatments. Since this drug is still in the clinical trial phase, it has...
A Study of RO7284755 Alone or in Combination With Atezolizumab in Patients with Advanced Solid Tumours
Background: RO7284755 is an experimental drug belonging to a new class of immunotherapies called "fusion proteins". This means that the researchers have "fused" together two drugs to produce a single compound capable of targeting two different molecules with a single medication. This fusion protein works by...
A Study for Patients with Advanced Kidney Cancer who are Currently on Treatment or in Follow-up for a Pembrolizumab Study (KEYNOTE-587)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. The purpose of this study is to assess...